Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

3.9%

3 terminated out of 77 trials

Success Rate

88.5%

+1.9% vs benchmark

Late-Stage Pipeline

40%

31 trials in Phase 3/4

Results Transparency

35%

8 of 23 completed with results

Key Signals

8 with results88% success

Data Visualizations

Phase Distribution

62Total
Not Applicable (10)
Early P 1 (4)
P 1 (5)
P 2 (12)
P 3 (14)
P 4 (17)

Trial Status

Completed23
Recruiting16
Unknown12
Active Not Recruiting11
Not Yet Recruiting10
Terminated3

Trial Success Rate

88.5%

Benchmark: 86.6%

Based on 23 completed trials

Clinical Trials (77)

Showing 20 of 20 trials
NCT07484230Phase 3WithdrawnPrimary

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT07424144Phase 3Active Not RecruitingPrimary

An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

NCT07520162Phase 3RecruitingPrimary

A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab

NCT06706817Phase 3Active Not RecruitingPrimary

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT05964465Phase 4CompletedPrimary

Mechanisms of Smell Improvement With Dupilumab.

NCT05891483Phase 2CompletedPrimary

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT07446738RecruitingPrimary

A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients

NCT05895929Early Phase 1CompletedPrimary

The Role of IL5 in Epithelial Cell Integrity

NCT06914908Phase 2Enrolling By InvitationPrimary

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

NCT07635433Early Phase 1Not Yet RecruitingPrimary

Thermosensitive Gel Nasal Spray With Stem Cell Exosomes, Mupirocin, and DNase I for Chronic Sinusitis

NCT06834360Phase 3Active Not RecruitingPrimary

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT05626257CompletedPrimary

Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

NCT06118554Not ApplicableRecruitingPrimary

3D Printing to Improve Nasal Irrigation Outcome

NCT06834347Phase 3Active Not RecruitingPrimary

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT03725956Not ApplicableRecruitingPrimary

Polysomnographic Findings in Nasal Polyposis

NCT05228041Active Not RecruitingPrimary

BIOlogics in Severe Nasal POlyposis SurvEy

NCT06454240Phase 2CompletedPrimary

A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

NCT06069310Active Not RecruitingPrimary

Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma

NCT04823585Phase 4Completed

Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)

NCT06516302Phase 3Active Not RecruitingPrimary

A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

Scroll to load more

Research Network

Activity Timeline